March 29, 2022
Aurobindo Receives FDA Approval for Bromfenac Ophthalmic Solution 0.09%
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Bromfenac Ophthalmic Solution 0.09%. Aurobindo Pharma’s Bromfenac Ophthalmic Solution, are an AT-rated generic equivalent to the reference listed drug (RLD), Bromday™ Ophthalmic Solution, of Bausch & Lomb. Bromfenac Ophthalmic Solution are indicated for: Postoperative inflammation and reduction of […]
